The bacterial CRISPR/Cas system has proven to be an efficient tool for genetic manipulation in various organisms. Here we show the application of CRISPR-Cas9 technology to edit the human Rhodopsin (RHO) gene in a mouse model for autosomal dominant Retinitis Pigmentosa. We designed single or double sgRNAs to knock-down mutant RHO expression by targeting exon 1 of the RHO gene carrying the P23H dominant mutation. By delivering Cas9 and sgRNAs in a single plasmid we induced an efficient gene editing in vitro, in HeLa cells engineered to constitutively express the P23H mutant RHO allele. Similarly, after subretinal electroporation of the CRISPR/Cas9 plasmid expressing two sgRNAs into P23H RHO transgenic mice, we scored specific gene editing as well as significant reduction of the mutant RHO protein. Successful in vivo application of the CRISPR/ Cas9 system confirms its efficacy as a genetic engineering tool in photoreceptor cells.
Introduction
G-protein coupled receptors (GPCR) are receptors for hormones, neurotransmitters, drugs, and sensory stimuli that play key roles in cellular metabolism and activity. 1 Point mutations in GPCR often cause protein misfolding and endoplasmic reticulum (ER)-retention associated with pathological conditions.
2 Rhodopsin (RHO) is one of the best characterized GPCR specifically expressed by rod photoreceptor cells and is composed by a protein opsin and a chromophore, 11-cis retinal. Photon absorption, inducing cis-trans isomerization of 11-cis retinal, triggers the phototransduction cascade required for vision. Dominant mutations in RHO represent a common cause of Retinitis Pigmentosa (RP), accounting for 25% of autosomal dominant RP and 8 to 10% of all RP 3 with over 140 different mutations identified so far (http://www.hgmd.cf.ac.uk). The majority of the biochemically characterized RHO mutants are likely misfolded and retained into the ER with a pathogenic mechanism well studied but still not fully characterized. [4] [5] [6] [7] [8] RP is an inherited form of retina degeneration leading to blindness with patients experiencing progressive loss of the peripheral field and, at later stages, compromising also the central part of the retina. Studies in transgenic mice bearing dominant RHO mutations showed that disease severity could be mitigated by transcriptional suppression using an allele-independent approach to target both mutant and wild-type alleles. 9 Botta et al. 10 recently showed the efficacy of RHO transcriptional repression mediated by artificial zinc finger proteins without canonical effector domain in pig retinas. Coupled to DNA-binding-mediated silencing, they provided human RHO cDNA to complement RHO transcriptional repression demonstrating the therapeutic potential of the combined silencing-replacement strategy in a large animal model.
Another strategy to tackle the autosomal dominant RP mutations spread all along the transcription unit is a mutation-independent knock-out of the RHO gene. This approach requires, as for the RHO transcriptional silencing, a combined replacement therapy with a wild type RHO gene. 11 Genetic perturbation mediated by the clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein 9 (Cas9) provides an alternative approach for gene silencing. The CRISPR-Cas system 12, 13 has been shown to have enormous potential for gene editing in a variety of hosts such as plants, 14 zebrafish, 15 flies, 16 mice, 17 monkeys, 18 and also in human cells. [19] [20] [21] The type 2 CRISPR/Cas9 system induces DNA double strand breaks (DSBs). The DSBs can stimulate cell repair mechanisms including nonhomologous end joining (NHEJ) and homology-directed repair (HR), but in most circumstances, NHEJ is the predominant mechanism for repairing DSBs. Small insertions and deletions created by NHEJ DNA repair can be used to generate frameshifts to abolish the expression of mutant alleles. 22 In this study, we addressed the efficacy of the CRISPR/ Cas9 system in rod photoreceptors to selectively generate loss-of-function mutations in the first exon of human RHO gene resulting in robust knock-down of RHO expression in vitro and in vivo, in the available P23H transgenic mouse model for RP bearing a human P23H mutant RHO minigene. Since no human cell line constitutively expressing RHO (normal or mutated) is available, we developed an in vitro cell-based system to test the CRISPR activity by engineering HeLa cells to constitutively express either wild type or mutant P23H RHO. We compared efficiencies at genomic, transcriptional, and protein levels in vitro and in rod cells in vivo of single versus double-combined single-guide RNAs (sgRNAs). An almost complete clearance of RHO expression in vitro and a strong reduction of human RHO in vivo were achieved combining two sgRNAs in a single effector plasmid. Editing analysis of predicted off-target sites by Cel-I assay did not detect mutations with frequencies ≥ 1%. Therefore, CRISPR/Cas9 disruption of RHO provides an excellent gene modification tool for future knock-out or therapeutic applications in the retina.
Results

Genome editing of the human RHO gene
To employ the CRISPR/Cas9 gene editing platform for correcting a wide range of RHO mutations, we created a couple of sgRNAs tailored to exon 1 of the RHO gene in order to abolish the expression of the vast majority of dominant mutations spread all along the transcription unit of RHO. 23 We employed the previously described Staphylococcus pyogenes nuclease that utilizes a human-codon optimized SpCas9 19, 24 and a chimeric sgRNA expression vector to direct efficient site-specific gene editing. We designed two protospacers in opposite DNA strands and in a tail-to-tail configuration meeting the 5′-NGG-3′ PAM requirement of SpCas9 to target exon 1 (Figure 1) . Small insertions or deletions created by NHEJ-based DNA repair within this exon can generate frameshift mutations within the selected protospacers knocking out RHO. The PAM sequence, 5′-GGG-3′, is recognized by sgRNA3, whereas sgRNA1, in reverse orientation, targets the PAM 5′-TGG-3′ present in the P23H mutant allele. The sgRNAs were intentionally targeted in the region with the single nucleotide C to A (nt 68 from ATG) conversion accounting for the P23H RHO mutation that represents our experimental in vitro and in vivo models. Although the PAM 5′-TGG-3′ is present only in the P23H allele, sgRNA1 could recognize the PAM 5′-GGG-3′ present in the wild type allele. Thereby, none of the two sgRNAs are mutation specific. The sgRNAs were cloned in the pX330 backbone to generate sgRNA1, sgRNA3, and 2sgRNA plasmids (see Supplementary Figure S1 ).
In vitro knock-down of mutant RHO expression by targeted gene editing We created HeLa cell lines stably expressing P23H-RHO because no cell line expressing RHO was available and thus mRNA and protein analyses could not be assessed after genome editing. To assess the RHO gene knock-down in vitro we generated HeLa stable clones using lentiviral vectors encoding the mutant P23H-RHO cDNA under the phosphoglycerate kinase (PGK) promoter. Basically, we transduced HeLa cells at low multiplicity of infection to favor the integration of few copies of lentivirus per cell and found ~20% of the cells producing RHO protein as detected by immunofluorescence analysis (data not shown). We cloned the bulk population by limiting dilution to isolate 34 clones showing a stable integration of the lentiviral vector. We determined the relative vector copy number (VCN) of the mutated RHO transgene in each clone by quantitative polymerase chain reaction (qPCR) (see Supplementary Figure S2a ). We selected two clones (#78 and #80) harboring two and one copy, respectively, and investigated the subcellular distribution of mutant RHO protein by immunofluorescence analysis. We expected no plasma membrane localization and ER retention of the mutant protein. 25, 26 In both clones P23H RHO protein could not be detected at the plasma membrane (see Supplementary Figure S3 ) but its localization was intracellular in the ER as defined by the colocalization with the ER-resident chaperone calnexin 27 (see Supplementary Figure S4a) . On the contrary, two HeLa clones (#42 and #73) harboring two copies each of a lentiviral vector expressing wild type RHO under the PGK promoter (see Supplementary Figure S2b Figure S4b ). Both clones expressing P23H behaved similarly, all experiments from now on were performed on clone #78 showing higher P23H RHO expression (see Supplementary Figure S6) .
We initially assessed frequency of gene editing in the P23H HeLa clone #78 2 days post-transfection by the Surveyor assay. We found that tested sgRNAs, either single or in couple in a single plasmid (2sgRNA) when coexpressed with the SpCas9 nuclease were able to mediate gene modification on the PGK-driven RHO expression cassette (Figure 2a) . Notably, HeLa cells transfected with the 2sgRNA plasmid and not treated with Cel I nuclease resulted in a full-length (FL) and in short-edited (SE) amplicons confirming the expected deletion of the region between the two selected protospacers (SE in Figure 2a ). Using specific primers recognizing the endogenous wild type locus of RHO we defined, as expected, that both sgRNAs are not mutation specific (data not shown).
The frequency of Indels in the P23H clone transfected with sgRNA1, sgRNA3, and 2sgRNA were measured by sequencing 130 PCR amplicons encompassing the target sites and resulted in 70, 76, and 82% Indels respectively ( Table 1) . The types of insertions and deletions generated by sgRNA1, sgRNA3, and 2sgRNA at this locus showed variable patterns of rearrangements of the coding sequence, insertion of up to 3 nt and deletion from 1 to 91 nucleotides (Figure 2b) . Deletion of region between the 2 PAMs was observed in the cells transfected with 2sgRNA plasmid. These deletions were also observed at mRNA level by reverse-transcriptase (RT)-PCR flanking the Cas9 target site on exon 1. Indeed a FL and SE P23H mRNAs were observed in the 2sgRNA treated clone. Conversely, the RT-PCR analysis performed on mRNA extracted from P23H HeLa clone transfected with sgRNA1 and sgRNA3 did not show SE bands (Figure 3a) . However in all CRISPR/Cas9 treated samples we observed a reduction of RHO expression compared with the untransfected or pX330-transfected cells (Figure 3a) . We quantified this reduction by Real time Taqman PCR and found a significant knock-down of RHO expression in samples exposed to sgRNA1, sgRNA3, and 2sgRNA plasmids (35, 25, 20%, respectively) (Figure 3b) .
Finally, we evaluated the RHO protein production by immunoblotting on total protein extracts from P23H HeLa clone #78 transfected with sgRNA1, sgRNA3, and 2sgRNA (Figure 3c ). We observed a strong reduction upon transfection with single sgRNAs or 2sgRNA, respect to untransfected cells. Based on genomic, transcriptomic, and protein results we selected 2sgRNA for the in vivo experiments.
Off-targets and cytotoxicity analyses
Before embarking in the in vivo experiments, we assessed the cytotoxicity and the off-targets of the designed sgRNAs in our in vitro model. Induction of apoptosis in CRISPR/Cas9-expressing cells was evaluated by labelling transfected HeLa clone #78 with 7-aminoactinomycin D (7-AAD) in combination with PE-Annexin V. This flow-cytometry-based assay allowed the discrimination of early apoptotic cells (AnnexinV + /7-AAD − ) and late apoptotic/necrotic cells (7-AAD + ). P23H HeLa clone #78 was transfected with a plasmid coding only for Cas9 fused to a GFP reporter (pL.CRISPR-GFP) and similar plasmids bearing also the sgRNAs employed in this study (pL.CRISPR-GFP.sgRNA1, pL.CRISPR-GFP.sgRNA3, and pL.CRISPR-GFP.2sgRNA). As control we transfected a plasmid coding only for the GFP reporter (pPGK.GFP). Cytotoxicity analysis was performed on the GFP + subpopulation scored in all samples. Similar profiles of early or late apoptotic/necrotic cells were observed in all samples with minimal induction of apoptosis in transfected cells (8-12% of early apoptotic cells and <10% of late apoptotic/necrotic cells) without significant differences among samples (analysis of variance (ANOVA), P ≤ 0.01) (see Supplementary Figure S7 ). These results proved no toxicity associate to the expression of the CRISPR/Cas9 system in human cells.
To predict the most likely off-target sites for the sgRNAs used to knock-down the RHO gene in this study, we used a public webserver (http://crispr.mit.edu) able to assess and prioritize potential CRISPR/Cas9 activity at off-target loci based on predicted positional bias of a given mismatch in the sgRNA protospacer sequence and the total number of mismatches to the intended target site.
The CRISPR design tool scored a total of 201 (111 for sgRNA1 and 90 for sgRNA3) potential off-target sites in the human genome and were listed in Supplementary Table S1a,b the top 20 off targets with a score ≥ 0.2. The top five potential off-target sites (0.4 ≤ score ≤ 0.7) for each sgRNA were assessed by the Surveyor assay in the P23H HeLa clone #78 edited with a high frequency ( Table 1) . None of the 10 predicted off-target loci had significant levels of off-target gene modification detectable by Cel I assay (Figure 4a,b and Supplementary Table S1 ).
Specific editing of human RHO in the P23H transgenic mouse model
To demonstrate the ability of the CRISPR/Cas9 system to edit the human RHO gene in the retina in vivo, we availed of a transgenic mouse model carrying the human P23H mutant alleles. 29 To better characterize expression of the human P23H-RHO transgene without interference by the murine Rho gene we bred the mice with Rho −/− knock-out mice 30 and generated mice expressing only the human P23H mutant RHO (Rho −/− P23H Tg ). We electroporated the 2sgRNA plasmid together with a plasmid expressing GFP to track the transfected cells in the retina. Electroporation was performed after subretinal injection as previously published. 31, 32 We evaluated expression of Cas9 in the electroporated retinas after dissection of the GFP + area ( Figure  5a ) and found a specific expression in the electroporated left eye that strongly correlated with expression of GFP (Figure 5b) . These data allowed us to be confident that GFP + cells were also expressing Cas9. We thus fluorescence-activated cell sorting (FACS)-sorted electroporated retinal cells based on GFP expression. We firstly confirmed the presence of photoreceptor cells in the negative and positive fractions by RT-PCR by analysis of Pde6b expression, a gene expressed only in rod photoreceptors (Figure 6a) , and then we evaluated genome editing in both fractions. GFP − cells did not show Indels (see Supplementary Figure S8 ) confirming that Cas9 expression was restricted to GFP + cells, on the contrary 4-33% editing, was scored in GFP + cells derived from 9 out 10 2sgRNA-treated retinas ( Table 2) . Specifically, Sanger sequencing of PCR amplicons (n = 404) surrounding the Cas9 target site of human P23H RHO gene edited in all 2sgRNA-treated mice, showed 84 edited sequences (21%), in particular 16% display the 24bp-deletion, 1% the inversion (insertion) of the sequence between the cleavage sites and 4% deletions of 5-25bp (Figure 6b) . No sign of genome editing was observed on the human P23H RHO gene in retinas injected with pX330 plasmid (see Supplementary Figure S9) or on the mouse Rho gene in retinas treated with 2sgRNA (Supplementary Figure S10) indicating a human allele-specific Cas9-mediated genome editing. To address the knock-down efficiency on P23H RHO expression we performed a human RHO specific RT-PCR on GFP + and GFP − cells sorted from the 2sgRNA-and pX330-injected retinas. All the GFP + retinal cells from the 2sgRNA-injected eyes showed the presence of the SE band corresponding to the deletions occurred on exon 1 of human RHO (Figure 6c) . The ratio between the SE P23H bands to the unmodified one FL in the same sample was analyzed and ranged between 12-35% (see Supplementary Figure S11 and Table 2 ). Finally, we wanted to define if targeting of the human RHO gene resulted in a reduction of RHO protein. To this aim, based on GFP expression, we cut the electroporated areas of four different or transfected with sgRNA1, sgRNA3, 2sgRNA, and pX330. The experiment was performed in triplicate and is presented as mean ± SEM (*P-value < 0.05, **P < 0.01). (c) Western blottings on total protein extracts to analyse RHO expression in untransfected (NC, negative control) and nuclease-treated P23H HeLa clone #78. The 35 kDa monomer RHO protein is strongly reduced after exposure to sgRNA1, sgRNA3, and 2sgRNA but not after exposure to the control pX330. The western blotting was normalized using anti-α-tubulin antibodies (lower panel). GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Table 2 ).
Discussion
In this study, we report the first in vivo CRISPR-Cas9-mediated editing of the human RHO gene carrying the Pro23His dominant mutation associated with autosomal dominant RP. 33 Differentially from Bakondi et al. 34 that targeted the dominant murine S334ter mutation (RhoS334) in a rat model for severe autosomal dominant RP, we developed a mutation-independent editing approach tailored to human RHO. Gene correction of dominant mutations can be tackled by replacement of the mutation/s through homologous recombination with a portion of the wild type gene or by knockingout the mutated allele followed by addition of the wild type coding sequence. Herein, we reported the feasibility of the CRISPR/Cas9 system to knock-down the human RHO gene in vivo in the P23H transgenic mouse model for RP. 29 This is a well-characterized animal model for RP generated with a human minigene derived from a patient. This animal model is characterized by intracellular protein accumulation and by a very fast retinal degeneration. 8, 29 The presence of the human gene allowed us to test gene editing in photoreceptor cells in vivo. A limitation was the fast progression of photoreceptor cell demise in the absence of the endogenous Rho in this model that hampered functional studies that require retinas at older ages than the time points analyzed in this study.
A primary advantage of the knock-out approach is that NHEJ is an active DNA repair mechanism in all cell types, whereas homologous recombination is typically only active in mitotic cells, thus strongly disfavored in neurons like photoreceptors. 35 Another advantage of this approach is the possibility to generate two DSBs resulting in the precise excision of a short DNA fragment between two Cas9-mediated cleavage sites occurring 3 bp upstream each PAM sequence. 13 Thus, the protein product of the edited gene is predictable. This is in contrast to the random Indels created by intraexonic action of a single nuclease or by double nickase strategies based on D10-SpCas9 that will lead to the creation of novel proteins from each DNA repair event.
RHO-specific knock-out was achieved in 70-82% of the RHO mutant alleles carried by HeLa cells transfected with single or double sgRNAs respectively. Among the 82% of 
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2sgRNA-edited alleles, we observed the predominance (64%) of precise junctions between the two DSBs reflecting the described property of Cas9 to generate blunt ends 3 bp upstream of the PAM sequence. 36 P23H RHO knockout was linked to a significant reduction of RHO expression in vitro. While the mRNA bearing the expected deletion upon 2sgRNA cleavage could be detected even if at low levels, the shorter RHO protein could not be distinguished with the resolution of the immunoblotting and notably we found a strong reduction of RHO protein that suggested instability of the protein, which was probably efficiently removed from the cell. Off-targets and cytotoxicity were addressed in P23H Figure 6a . Four left 2sgRNA electroporated retinas (L-2sgRNA) were compared with the contralateral not-injected right retinas (R-NI) and showed reduction of RHO visible as monomer at 35 kDa and dimers/multimers at higher molecular weights. Four control left pX330 electroporated retinas (L-pX330) were compared with the contralateral not-injected right retinas (R-NI) and showed no significant change of RHO. The western blotting was normalized using antirecoverin antibodies, detecting a protein expressed in photoreceptors (lower panel). 
R-NI HeLa cells transfected with CRISPR/Cas9 system. We did not detect cleavage activity on the top 10 ranking off-target sites by CelI assay, able to detect mutations with frequencies ≥ 1%. To deeply address the off-target issue of sgRNAs with therapeutic relevance for a clinical application of the CRISPR/Cas9 system in vivo, a more appropriate method such as GUIDE-seq 37 should be performed. Alternatively, the therapeutic sgRNAs could be delivered together with the high fidelity SpCas9 38 which is reported to have even lower offtarget cleavage events.
Most importantly, we demonstrated the feasibility of knocking-down the expression of mutated RHO in vivo, in the transgenic P23H mouse model. After retinal electroporation of the 2sgRNA the frequency of Indels reflected a lower knock-out efficiency than in vitro likely due to a lower copy number of Cas9-carrying plasmids delivered in vivo and to an already reported uncomparable genome editing efficiency in vitro versus in vivo. 39 However efficient knockdown in GFP + sorted cells was observed, and resulted in a significant reduction of mutant P23H protein. The different efficiencies scored in the analyses at distinct levels, i.e., genomic, transcript, and protein, may be explained by the fact that not more than one analysis could be performed in the same animal due to the limited availability of the biological samples. Secondly, the sensitivities of the techniques are different and cannot be directly compared. Notably, reduction of human RHO transcript at similar levels (26%) was found sufficient to protect photoreceptor degeneration in the P347S mouse model. 9 Recently Botta et al. 10 reported 38% RHO transcriptional repression in the porcine retina followed by injection of an AAV8 vector carrying a RHO-specific DNAbinding repressor. Therefore, the levels of gene editing and mutant protein knock-down that we detected in the electroporated area of the retinas are in line with previous studies. Here we delivered the entire CRISPR/Cas9 system and sgRNAs using a single plasmid and, at the moment, the gene therapy delivery system in the clinic for the retina is based on AAV 40 that cannot accommodate the entire system but CRISPR/hSpCas9 components should be incorporated into two AAV8 vectors. This may improve delivery because AAV8 is very efficient for photoreceptor transduction but it may reduce genome editing due to the required coinfection by two viruses. This limitation may be overcome by the recently cloned Cas9 genes from other species such as N. meningitidis 41 and Staphylococcus aureus 21, 42, 43 that are small enough to be efficiently packaged together with the sgRNAs into a single AAV8 vector.
This study demonstrates that CRISPR/Cas9 genome editing is a robust, easily programmable method to rapidly generate targeted frameshifts or genomic deletions in the retina. 
Materials and methods
Plasmids. The pCCL-PGK.wtRHO and pCCL-PGK.P23H.RHO plasmids were generated by cloning the wtRHO.cDNA and P23H.RHO.cDNA (kindly provided by A. Auricchio) in pCCL. LV.PGK vector downstream PGK promoter. 44 The sgRNA1 and sgRNA3 plasmids were obtained by cloning the sgRNA1 and sgRNA3, respectively, in pX330 by oligo annealing into BbsI sites (www.addgene.org). The 2sgRNA plasmid was achieved by cloning the U6-sgRNA3 into pX330-sgRNA1 downstream sgRNA1, in the same orientation. The pL.CRISPR-GFP. sgRNA1 and pL.CRISPR-GFP.sgRNA3 plasmids were generated by cloning sgRNA1 and sgRNA3, respectively, in pL.CRISPR-EFS.GFP (www.addgene.org) by oligo annealing into BsmBI sites. The pL.CRISPR-GFP.2sgRNA was obtained by cloning the U6-sgRNA3 into pL.CRISPR-GFP.sgRNA1 downstream sgRNA1, in the same orientation.
Cell culture and viral production. HeLa and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin (Lonza Ltd, Basel), Switzerland). Lentiviral stocks (LV) pseudotyped with the vesicular stomatitis virus G protein were prepared by transient cotransfection of HEK293T cells with transfer vector, pMD.Lg/pRRE.Int packaging plasmid, pMD2.VSV-G envelope-encoding plasmid, and pRSV-Rev. 45 
Transfections of HeLa cells, isolation of single cell clones, and VCN determination. Transfection 2.5 × 10
5 HeLa cells were transfected with Lipofectamine 3000 (ThermoFisher Scientific Monza, Italy). Each transfection reaction contains 2.5 ìg of DNA, 7.5 ìl of Lipofectamine 3000 and 5 ìl of Reagent P3000 and the mix was added to the cells accordingly to the manufacture's protocol.
Isolation of single cell clones.
HeLa cells were transduced with LV for P23H RHO expression and the following day were limiting diluted to obtain a concentration of 0.3 cell/well in a 96 well plate. Genomic DNAs (gDNAs) extracted from single cell clones were screened by PCR on the RHO expression cassette as following: primers PGK.F and hRHO.1ex.R (Supplementary Table S2 ), PCR conditions: 30″ at 94°C, 30″ at 58°C, and 30″ at 72°C for 30 cycles. PCR products were separated on 1%TBE (Tris/Borate/EDTA)-agarose gels and stained with ethidium bromide for analysis. VCN determination. qPCR was conducted with 20 ng gDNA in a 25 µl reaction using TaqMan Universal PCR Master Mix and probes specific for human RHO and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (hRHO: Hs00892431m1; GAPDH: Hs03929097_g1Applied Biosystem Milan, Italy). Reactions were performed at 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. The relative copy number was normalized to the GAPDH in the same gDNA by using the 2 −ΔΔCT quantification. 28 The channels of single RGB images were split into grayscale pictures and the red and green channels used for analysis. A region of interest in the green channel was created by free hand drawing around the RHO fluorescence in single cells and used for calculating PCC (see 28 for details). PCC values can range from +1 to −1. Whereas a value of 1 represents perfect correlation (protein retained into the ER), value −1 represents perfect but inverted correlation and values near zero represent distributions of fluorescent signals that are uncorrelated with one another. 28 The mean PCC-values derived from five cells for each clone were used for statistical analysis by Student's unpaired t-test. All data are presented as mean values ± standard errors of the means (SEMs).
Surveyor assay and DNA sequence analysis. For the Cel-I nuclease assay to detect CRISPR/Cas9-mediated mutations, the SURVEYOR Mutation Detection Kit (Transgenomic, Omaha, NE) was used in accordance with the manufacturer's protocol. Briefly, 48 hours after transfection, genomic DNA was extracted using the DNeasy MiniKit (QIAGEN Hilden, Germany). PCR to detect the on target cleavage was performed with the primers PGK.F, and hRHO.1ex.R (Supplementary Table S2 ). To amplify the off targets predicted by a public webserver (http://crispr.mit.edu), we designed several primers listed in Supplementary Table S2 . The amplification products were denatured and digested by the Cel-I nuclease, and then subjected to 2% agarose gel electrophoresis for on-targets and off-targets. For DNA sequence analysis of the on target Indels, the PCR products were subcloned into a PCR2.1 TOPO vector (ThermoFisher Scientific) and Sanger sequenced (Eurofin s.r.l Vimodrone, Italy). Statistical analysis. Data were analyzed for statistical significance using two-way ANOVA or Student's t-test. All values in each group were expressed as the mean ± SEM. All group comparisons were considered significant at P < 0.05, P < 0.01, P < 0.001. ). This knock-out does not express murine Rho although the first exon is intact and could, potentially, be recognized by the designed sgRNAs. All mice were genotyped as previously published. 29, 30 The pX330 or 2sgRNA, together with the plasmid pCAG-GFP expressing GFP, were electroporated in Rho −/−
P23H
Tg neonatal mice as previously published. 31, 32 In brief, newborn murine pups were anesthetized by chilling on ice and eyelids were opened using a scalpel. After piercing the sclera with a 30-gauge needle, 0.5 µl of DNA solution (6 mg/ml) was delivered subretinally by using a Hamilton syringe. After DNA injection five 90 V square pulses of 50 milliseconds duration were applied with a T820 electroporation system (BTX, San Diego California, USA). Electroporated retinas were harvested 7 days after electroporation and electroporated areas were dissected under a Leica fluorescent stereoscope and proteins extracted for western blotting analysis. For genomic and mRNA analyses the entire electroporated retinas were treated in papain (0.6 U in 30 µl) for 30 minutes, the enzyme was diluted 33 times with DMEM in the presence of DNAse (12.5 U) and cells dissociated by trituration with a Gilson pipet. After washing with DMEM, dissociated retina cells were sorted at 488 nm based on GFP expression by FACS (BD FACSAriaIII Cell Sorter Milan, Italy).
Retinal protein extracts and western blotting analysis. Retinas were dissected in PBS. Tissue was disrupted in lysis buffer (PBS, 17 mmol/l CHAPS, protease inhibitor cocktail from Sigma) for 30 minutes at 4°C. After centrifugation at 17,400×g for 30 minutes the supernatant was collected.
Equivalent amounts of protein extracts (30 µg for HeLa cells, 5 µg for analyses of transgenic human RHO in the retina and 10 ng for wild type murine Rho in the retina) were resolved using sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and immunoblotting was performed following standard procedures. The antibodies used were: anti-RHO (1D4, recognizing an epitope at the C-term, 1:10,000; Sigma), antirecoverin (1:2,000, Millipore), anti-α-tubulin (1:2,500, Sigma). Quantification was performed by densitometry analysis of scanned images using Image J software, corrected by background, and plotted as protein levels of RHO over the reference protein. Data are mean ± SD of three blots with proteins derived from four animals from two biological replicates. Figure S1 . Schematic representation of pX330 and pX330-derived plasmids carrying Cas9 and one or more gRNAs. Figure S2 . qPCR on P23H RHO and wt RHO. Figure S3 . Expression of RHO in stable HeLa clones. Figure S4 . Generation of an in vitro model carrying the P23H RHO mutation. Figure S5 . Localization of WT RHO in stable clones. Figure S6 . Quantitative expression of P23H Rhodopsin in clone #80 respect to the clone #78. Figure S7 . Flow cytometry analysis of cell toxicity induced by the CRISPR/Cas9 system. Figure S8 . Indel spectrum determined by TIDE analysis on human RHO gene in the GFP-fraction of mouse retinas treated with 2sgRNA. Figure S9 . Indel spectrum determined by TIDE analysis on human RHO gene in the GFP+ fraction of mouse retinas treated with pX330. Figure S10 . Indel spectrum determined by TIDE analysis on mouse Rho gene in the GFP+ fraction of mouse retinas treated with 2sgRNA. Figure S11 . Densitometry analysis of short edited respect to the full length mRNA RHO in the GFP+ cells from 2sgRNA-electroporated retinas. Figure S12 . Densitometry analysis and scatter plot of RHO protein levels. Table S1 . Predicted off-targets for sgRNA1 and sgRNA3. Table S2 . Primers used in this study.
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